Table 1 Patient characteristics, adverse events, and response to nivolumab treatment
Patient 1 | Patient 2 | Patient 3 | |
|---|---|---|---|
Age | 47 | 25 | 55 |
Sex | Male | Male | Male |
Prior therapies (no.) | 6 | 6 | 5 |
Stem cell source | Matched-related | Matched-related | Haploidentical and umbilical cord blood |
Conditioning regimen | Reduced intensity | Reduced intensity | Reduced intensity |
T cell depleted graft | Yes | Yes | Yes |
Prior GVHD | No | Chronic GVHD of gut | Chronic oral GVHD |
Days to relapse following AlloHSCT (no.) | 181 | 2456 | 389 |
Localization and size of relapse | Diffuse bone and splenic involvement | Multifocal adenopathy in mediastinum, retroperitoneum and pelvis. Largest lymph node 2.3 × 1.5 cm in mediastinum | Multifocal adenopathy in neck, chest, abdomen and pelvis. Largest lymph node 4.2 × 1.8 cm in right axilla |
Prior DLI | No | Yes | No |
Immune-related adverse events | Grade 2 Keratoconjunctivitis | Grade 3 Inflammatory polyarthritis and grade 2 keratoconjunctivitis | Grade 1 Rash |
Response to nivolumab | Partial response | Partial response | Partial response |
Duration of response | 6 Months+ | 10 Months+ | 14 Months+ |
Donor CD3+ chimerism before and after treatment | 18 to 49% | Not available | Not available |